grant
Studies of the SARS-CoV-2 Spike Protein
Organization DIVISION OF BASIC SCIENCES - NCILocation UNITED STATES
NIHUS FederalResearch GrantFY20252019 novel corona virus2019 novel coronavirus2019-nCoV2019-nCoV S protein2019-nCoV spike glycoprotein2019-nCoV spike protein2019-nCoV vaccine2019-nCoV variant2019-nCoV variant forms2019-nCoV variant strains7S Gamma GlobulinACE2AdjuvantAffectAir MovementsAirway challengeAirway mucosaAlum AdjuvantAnimal ModelAnimal Models and Related StudiesAnimalsAntibodiesAntibody SpecificityAntibody titer measurementAntigensAppearanceB.1.1.529B.1.617.2BindingBlood SerumBody Weight decreasedBronchoalveolar Lavage FluidCD8 CellCD8 T cellsCD8 lymphocyteCD8+ T cellCD8+ T-LymphocyteCD8-Positive LymphocytesCD8-Positive T-LymphocytesCOVID-19COVID-19 S proteinCOVID-19 infectionCOVID-19 predispositionCOVID-19 preventionCOVID-19 spikeCOVID-19 spike glycoproteinCOVID-19 spike proteinCOVID-19 susceptibilityCOVID-19 vaccineCOVID-19 variantCOVID-19 variant formsCOVID-19 variant strainsCOVID-19 virusCOVID-19 virus infectionCOVID-19 vulnerabilityCOVID19 infectionCOVID19 virusCV-19Cancer cell lineCell BodyCell LineCellLineCellsChemotactic CytokinesCholesterolCoV-2CoV2Coronavirus Infectious Disease 2019Coronavirus disease 2019 predispositionCoronavirus disease 2019 susceptibilityCoronavirus disease 2019 vulnerabilityCoupledCricetinaeDNA VaccinesDataDelta variantDendritic CellsDietDiseaseDisorderDoseEdodekin AlfaElectroporationEpithelial CellsEpitheliasin GeneFemaleFormulationGM-CSFGenderGender BiasGranulocyte-Macrophage Colony-Stimulating FactorHIV vaccineHIV/AIDS VaccinesHamstersHamsters MammalsHistamine-Producing Cell-Stimulating FactorHomologous Chemotactic CytokinesHumanHuman Cell LineIL-12IL-15IL12IL15IL15 ProteinIgAIgGImmuneImmune responseImmunesImmunityImmunizeImmunoglobulin AImmunoglobulin GIn VitroIndustrializationInfectionInfection preventionInnate ImmunityIntercrinesInterferon Type IInterleukin-12Interleukin-15Interleukin-15 PrecursorLicensingLigandsLungLung Respiratory SystemM mulattaM. mulattaMGC9721MacacaMacaca mulattaMacaca rhesusMacaqueMalignant Tumor of the LungMalignant neoplasm of lungMedical centerMessenger RNAMethodsMiceMice MammalsModelingModern ManMolecular InteractionMolgramostinMonitorMorbidityMorbidity - disease rateMouse StrainsMucosaMucosal ImmunityMucosal TissueMucous MembraneMurineMusMyelogenousMyeloidMyeloid CellsMyeloid-derived suppressor cellsN-3 polyunsaturated fatty acidNKSFNSCLCNSCLC - Non-Small Cell Lung CancerNaked DNA VaccinesNasalNasal Passages NoseNasal cavityNative ImmunityNatural ImmunityNatural Killer Cell Stimulatory FactorNon-Small Cell Lung CancerNon-Small-Cell Lung CarcinomaNon-Specific ImmunityNonspecific ImmunityNoseObesityOmega-3 Fatty AcidsOmega-3 PUFAOmega-3 Polyunsaturated Fatty AcidOmega3Omicron variantOropharyngealOropharynxOropharynxsPRSS10PersonsPredisposed to COVID-19Predisposed to SARS-CoV-2Predisposed to Severe acute respiratory syndrome coronavirus 2Prevent infectionProductionProteinsPublic HealthPublishingPulmonary CancerPulmonary malignant NeoplasmRNA vaccineRNA-based vaccineReagentReceptor ProteinRecombinant DNA VaccinesRecombinantsRespiratory EpitheliumRespiratory MucosaRespiratory System, Nose, Nasal PassagesRhesus MacaqueRhesus MonkeyRisk ReductionRoleRouteSARS corona virus 2SARS-CO-V2SARS-COVID-2SARS-CoV-2SARS-CoV-2 B.1.1.529SARS-CoV-2 B.1.617.2SARS-CoV-2 SSARS-CoV-2 S proteinSARS-CoV-2 deltaSARS-CoV-2 infectionSARS-CoV-2 omicronSARS-CoV-2 omicron variantSARS-CoV-2 predispositionSARS-CoV-2 spikeSARS-CoV-2 spike glycoproteinSARS-CoV-2 spike proteinSARS-CoV-2 susceptibilitySARS-CoV-2 vaccineSARS-CoV-2 variantSARS-CoV-2 variant formsSARS-CoV-2 variant strainsSARS-CoV-2 vulnerabilitySARS-CoV2SARS-CoV2 infectionSARS-associated corona virus 2SARS-associated coronavirus 2SARS-coronavirus-2SARS-coronavirus-2 vaccineSARS-related corona virus 2SARS-related coronavirus 2SARSCoV2SIS cytokinesSIV VaccinesSerumSevere Acute Respiratory Coronavirus 2Severe Acute Respiratory Distress Syndrome CoV 2Severe Acute Respiratory Distress Syndrome Corona Virus 2Severe Acute Respiratory Distress Syndrome Coronavirus 2Severe Acute Respiratory Syndrome CoV 2Severe Acute Respiratory Syndrome CoV 2 vaccineSevere Acute Respiratory Syndrome-associated coronavirus 2Severe Acute Respiratory Syndrome-related coronavirus 2Severe acute respiratory syndrome associated corona virus 2Severe acute respiratory syndrome coronavirus 2Severe acute respiratory syndrome coronavirus 2 S proteinSevere acute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 predispositionSevere acute respiratory syndrome coronavirus 2 spike glycoproteinSevere acute respiratory syndrome coronavirus 2 spike proteinSevere acute respiratory syndrome coronavirus 2 susceptibilitySevere acute respiratory syndrome coronavirus 2 vaccineSevere acute respiratory syndrome coronavirus 2 vulnerabilitySevere acute respiratory syndrome related corona virus 2Sex BiasSiteSouth AfricanStrains Cell LinesStructure of respiratory epitheliumT cell responseT-CellsT-LymphocyteT8 CellsT8 LymphocytesTC-GM-CSFTLR3TLR3 geneTMPRSS2TMPRSS2 geneTestingTexasTimeToll-Like Receptor 3TouchTouch sensationTransmissionTumor-Cell Human GM Colony-Stimulating FactorUniversitiesVaccinatedVaccinationVaccinesVariantVariationVascular Endothelial CellVeiled CellsViralViral VaccinesVirionVirusVirus ParticleWeight LossWeight ReductionWorkWuhan coronavirusadiposityair flowairflowairway epitheliumalumaluminum sulfateangiotensin converting enzyme 2angiotensin converting enzyme IIantibody titeringbody weight lossbooster dosebooster shotbooster vaccinechemoattractant cytokinechemokinecompare to controlcomparison controlcoronavirus disease 2019coronavirus disease 2019 S proteincoronavirus disease 2019 infectioncoronavirus disease 2019 preventioncoronavirus disease 2019 spike glycoproteincoronavirus disease 2019 spike proteincoronavirus disease 2019 vaccinecoronavirus disease 2019 variantcoronavirus disease 2019 variant formscoronavirus disease 2019 variant strainscoronavirus disease 2019 viruscoronavirus disease-19coronavirus disease-19 preventioncoronavirus disease-19 vaccinecoronavirus disease-19 viruscoronavirus infectious disease-19corpulencecultured cell linedietsdimerdisease controldisease preventiondisorder controldisorder preventionelectroporative deliveryexperiencegender differencegender-associated differencegene electrotransferhCoV19health goalshost responsehuman immunodeficiency virus vaccineimmune system responseimmunogenimmunogenicityimmunopathologyimmunoresponseimmunosuppressive myeloid cellsimprovedin vivoindicated preventionindicated preventive interventionsindicated preventive measureinfected with COVID-19infected with COVID19infected with SARS-CoV-2infected with SARS-CoV2infected with coronavirus disease 2019infected with severe acute respiratory syndrome coronavirus 2lung cancerlung cancer cellmRNAmRNA vaccinemRNA-based vaccinemalemodel of animalmucosal vaccinemyeloid suppressor cellsmyeloid-derived suppressive cellsn-3 Fatty Acidsn-3 PUFAnCoV vaccinenCoV-19 vaccinenCoV19 vaccinenCoV2nano particlenano-sized particlenanoparticlenanosized particleneutralizing antibodynon-human primatenonhuman primateomega-3omega-3somicron variant of COVID-19omicron variant of SARS-CoV-2oral pharyngealpre-clinical studypreclinical studypredisposed to Coronavirus disease 2019preventprevent COVID-19prevent coronavirus disease 2019preventingprevention directed at individualsreceptorreceptor bindingreceptor boundreduce riskreduce risksreduce that riskreduce the riskreduce these risksreduces riskreduces the riskreducing riskreducing the riskrespiratory challengerespiratory tract epitheliumresponserisk-reducingsevere acute respiratory syndrome coronavirus 2 B.1.1.529severe acute respiratory syndrome coronavirus 2 B.1.617.2severe acute respiratory syndrome coronavirus 2 variantsevere acute respiratory syndrome coronavirus 2 variant formssevere acute respiratory syndrome coronavirus 2 variant strainssimian immunodeficiency virus vaccinessocial rolespike proteins on SARS-CoV-2suppressive myeloid cellssusceptible to COVID-19susceptible to Coronavirus disease 2019susceptible to SARS-CoV-2susceptible to Severe acute respiratory syndrome coronavirus 2tactile sensationthymus derived lymphocytetransmission processvaccination studyvaccination trialvaccine against 2019-nCovvaccine against COVID-19vaccine against SARS-CoV-2vaccine against SARS-coronavirus-2vaccine against Severe Acute Respiratory Syndrome CoV 2vaccine against Severe acute respiratory syndrome coronavirus 2vaccine boostvaccine candidatevaccine candidates against SARS-CoV-2vaccine for novel coronavirusvaccine studyvaccine trialvaccines preventing COVIDvaccines to prevent COVIDvariants of concernviral transmissionvirus transmissionvulnerable to COVID-19vulnerable to Coronavirus disease 2019vulnerable to SARS-CoV-2vulnerable to Severe acute respiratory syndrome coronavirus 2wt-loss♀♂
Description preview
In vivo vaccine studies in macaques and hamsters: Rhesus macaques have been primed IM with S1 spike protein in different adjuvants and boosted systemically with spike in alum or mucosally intranasally with spike in nanoparticles (NPs) with IL-15 and TLR ligand adjuvants. We have found and published that NPs containing S1 spike protein delivered…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click